Go Pro

Healthcare Stocks List

This page shows information about the 50 largest healthcare sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck & Co., Inc..

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,184.38 +2.49 (+0.21%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$1,183.80 -0.58 (-0.05%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • Eli Lilly and Co recently secured FDA approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes, which offers a more convenient alternative to daily injections and strengthens the company's position in the diabetes care market.
  • The company demonstrated strong financial performance in its most recent earnings report, with actual revenue of $22.97 billion significantly exceeding the consensus estimate of $20.82 billion, indicating robust demand for its pharmaceutical products.
  • Analysts maintain a Moderate Buy consensus rating with a price target of $1,304.86, suggesting that the current stock price of $1,184.38 offers potential upside as the market continues to value the company's growth in obesity and diabetes treatments.

Cons of Eli Lilly and Company

  • Despite strong growth, Eli Lilly and Co faces intensifying competition in the GLP-1 market, with rivals like Novo Nordisk actively pursuing strategies to regain market share, which could pressure pricing and volume growth for the company's obesity and diabetes drugs.
  • The company's valuation remains high with a P/E ratio of 39.74, which may limit upside potential if growth rates slow or if the market becomes more sensitive to pricing pressures in the pharmaceutical sector.
  • Recent insider activity shows selling pressure, with executives such as Patrik Jonsson and Anat Hakim selling shares in August 2026, which some investors may interpret as a signal of limited near-term upside or personal financial needs rather than confidence in future growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.11 trillion
P/E Ratio
39.74
Consensus Rating
Moderate Buy
Consensus Price Target
$1,308.39 (+10.5% Upside)
Volume
1.92 million shares
Average Volume
2.22 million shares
Today's Range
$1,160.84
▼
$1,190.00
50-Day Range
$1,115.53
▼
$1,280.62
52-Week Range
$716.08
▼
$1,292.65
Dividend Yield
0.59%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$271.58 +0.90 (+0.33%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$270.63 -0.95 (-0.35%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Johnson & Johnson recently demonstrated significant clinical progress in its oncology franchise, with new Phase 3 modeling for the TECVAYLI plus DARZALEX FASPRO combination indicating that approximately 87% of early-line relapsed/refractory multiple myeloma patients could face mortality risk comparable to the general population, supporting long-term growth potential.
  • The company's neuroscience portfolio is expanding as CAPLYTA delivered statistically significant and rapid symptom improvement in a Phase 3 study of bipolar I mania, which could support broader revenue growth if approved for this additional indication alongside bipolar depression and schizophrenia.
  • Johnson & Johnson is strengthening its immunology pipeline with the FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, providing a potential successor to declining STELARA sales and expanding its market reach in this therapeutic area.

Cons of Johnson & Johnson

  • At a P/E ratio of 31.40, Johnson & Johnson's valuation leaves less room for disappointment, as analysts note that the stock has substantially outperformed peers even though revenue growth has been slower, making investors more sensitive to any execution risks or slowdowns in newer products.
  • Recent insider activity shows a trend of selling, with EVP Timothy Schmid selling 33,597 shares on September 2nd and EVP Elizabeth Forminard selling 15,918 shares on August 6th, indicating that corporate insiders have reduced their ownership stakes in the company.
  • Reports suggest that Johnson & Johnson may divest its DePuy Synthes orthopedics unit, which could introduce uncertainty regarding the company's portfolio strategy and the near-term effects of such a significant structural change on its business operations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$653.61 billion
P/E Ratio
31.47
Consensus Rating
Moderate Buy
Consensus Price Target
$274.13 (+0.9% Upside)
Volume
4.06 million shares
Average Volume
6.05 million shares
Today's Range
$269.26
▼
$272.25
50-Day Range
$248.83
▼
$278.66
52-Week Range
$177.32
▼
$281.07
Dividend Yield
1.98%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$264.45 -0.67 (-0.25%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$264.60 +0.15 (+0.06%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie recently secured European Commission approval for Rinvoq for children aged two and older with active polyarticular juvenile idiopathic arthritis, expanding the drug's addressable population to 11 approved indications in Europe and reinforcing its long-term growth potential in the immunology sector.
  • The company demonstrated strong financial performance in the most recent quarter, reporting revenue of $16.99 billion, which exceeded the consensus estimate of $16.80 billion and represented a 10.2% year-over-year increase, while also beating earnings per share estimates with $3.65 compared to the expected $3.61.
  • AbbVie has established a partnership with Iambic, a company that recently filed for an IPO, to accelerate AI-driven drug discovery in immunology, neuroscience, and oncology, providing the firm with access to advanced computational capabilities and future pipeline opportunities.

Cons of AbbVie

  • AbbVie is trading at a price-to-earnings ratio of 74.87, which is significantly elevated compared to many peers, raising concerns about valuation sustainability as some analysts argue that revenue pressure and weakening earnings support a sell view despite recent beats.
  • The company faces challenges in its oncology portfolio, with Imbruvica experiencing decline, and while AbbVie is working to rebuild this segment with newer therapies, the transition period may impact overall revenue growth and market perception of the company's oncology leadership.
  • Recent insider activity includes significant share sales, such as EVP Nicholas Donoghoe selling 32,710 shares in August 2026, which may signal reduced confidence from company executives or a desire to diversify personal holdings, potentially affecting investor sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$467.03 billion
P/E Ratio
74.70
Consensus Rating
Moderate Buy
Consensus Price Target
$276.64 (+4.6% Upside)
Volume
2.53 million shares
Average Volume
3.91 million shares
Today's Range
$262.59
▼
$266.00
50-Day Range
$243.64
▼
$265.63
52-Week Range
$190.75
▼
$269.39
Dividend Yield
2.62%
Merck & Co., Inc. stock logo

4. Merck & Co., Inc. NYSE:MRK

$148.75 +0.77 (+0.52%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$148.50 -0.25 (-0.16%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck recently announced that its investigational drug remigromig met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for adults with diabetic macular edema, a potentially first-in-class therapy that could open a new therapeutic avenue for the company.
  • The FDA approved a label update for WINREVAIR to include data from the Phase 3 HYPERION trial, expanding its use to recently diagnosed adults with pulmonary arterial hypertension and strengthening the commercial opportunity for this growth asset.
  • Bank of America maintains a Buy rating on the stock, citing confidence from Merck’s chief medical officer and multiple potential oncology and other pipeline readouts expected over the next 12 to 18 months that could support a re-rating of the shares.

Cons of Merck & Co., Inc.

  • Merck has a high price-to-earnings ratio of 118.36, which indicates that the stock is trading at a significant premium relative to its earnings, potentially limiting upside potential if growth does not accelerate.
  • Insiders have sold a total of 228,238 shares of company stock valued at $29,977,783 over the last ninety days, including significant sales by EVPs David Williams and Chirfi Guindo, which may signal a lack of confidence in the current valuation.
  • One analysis warned that the recent "melt-up" in the stock price could lead to further profit-taking and assigned a more cautious rating tied to the risks of Merck’s longer-term portfolio renewal.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$367.07 billion
P/E Ratio
119.00
Consensus Rating
Moderate Buy
Consensus Price Target
$154.24 (+3.7% Upside)
Volume
8.28 million shares
Average Volume
9.47 million shares
Today's Range
$147.48
▼
$149.98
50-Day Range
$124.41
▼
$156.54
52-Week Range
$77.69
▼
$156.92
Dividend Yield
2.29%
UnitedHealth Group stock logo

5. UnitedHealth Group NYSE:UNH

$377.02 +2.01 (+0.54%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$377.09 +0.07 (+0.02%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • UnitedHealth Group demonstrated strong earnings momentum in the second quarter of 2026, reporting earnings per share of $6.38, which significantly exceeded the analyst consensus estimate of $4.94, indicating that the company's operational improvements are translating into tangible financial results for shareholders.
  • Management has raised its full-year 2026 adjusted earnings per share guidance to a range of $19.50 to $20.00, a substantial increase from previous estimates, which signals confidence in the company's ability to sustain margin expansion and profitability growth throughout the remainder of the fiscal year.
  • The stock is currently trading at $377.02, which is well below the consensus analyst price target of $456.56, suggesting that the market may be undervaluing the company's recent turnaround and potential for further upside as it continues to execute its strategic initiatives.

Cons of UnitedHealth Group

  • Revenue growth has nearly stalled, with second-quarter 2026 revenue of $112.03 billion showing only a 0.4% increase compared to the same period last year, raising concerns about the company's ability to drive top-line growth while relying heavily on cost controls to boost earnings.
  • The commercial segment's cost trend ran modestly above 11% in the first half of 2026, with issues related to arbitration abuse and provider coding intensity squeezing margins, a problem that management has pushed the recovery timeline for past 2027, indicating prolonged pressure on profitability.
  • CEO Patrick Conway has engaged in multiple stock sales in 2026, including a recent transaction on August 21, 2026, where he sold 1,169 shares at an average price of $390.00, which some investors may interpret as a signal of reduced insider confidence or a desire to diversify personal holdings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$338.03 billion
P/E Ratio
24.26
Consensus Rating
Moderate Buy
Consensus Price Target
$456.56 (+21.1% Upside)
Volume
4.07 million shares
Average Volume
5.00 million shares
Today's Range
$371.17
▼
$379.17
50-Day Range
$370.76
▼
$436.19
52-Week Range
$255.96
▼
$461.62
Dividend Yield
2.47%
Novartis stock logo

6. Novartis NYSE:NVS

$145.49 +1.92 (+1.34%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$144.92 -0.58 (-0.40%)
As of 09/25/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG recently secured a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for Cosentyx in the treatment of polymyalgia rheumatica, a significant regulatory milestone that expands the drug's market potential in the EU with a final decision expected by November 2026.
  • The company demonstrated strong financial performance in its most recent quarterly report, posting earnings per share of $2.41 and revenue of $14.95 billion, which reflects a robust net margin of 23.29% and a return on equity of 38.56%, indicating efficient capital utilization and profitability.
  • Novartis AG is currently trading at $143.48, which is below the consensus price target of $153.00 set by Wall Street analysts, suggesting potential upside for investors as the stock remains undervalued relative to professional forecasts despite recent volatility.

Cons of Novartis

  • Novartis AG has faced a series of recent clinical setbacks, including the discontinuation of its ALS drug lifonebart after failing to meet endpoints in a Phase II trial, which raises concerns about the efficiency and success rate of its research and development pipeline.
  • The stock experienced a significant gap down of approximately 20% on September 8, 2026, dropping from a previous close of $159.99 to $139.49, reflecting sharp negative market sentiment and potential risk aversion among investors following recent news.
  • Wall Street analysts have issued mixed signals, with Deutsche Bank downgrading the stock from "buy" to "hold" and HSBC only raising its rating to "hold" with a target price of $136.00, which is below the current trading price, indicating a lack of strong bullish conviction from major financial institutions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$277.56 billion
P/E Ratio
21.94
Consensus Rating
Hold
Consensus Price Target
$153.00 (+5.2% Upside)
Volume
1.17 million shares
Average Volume
2.55 million shares
Today's Range
$144.00
▼
$145.51
50-Day Range
$137.22
▼
$163.27
52-Week Range
$121.57
▼
$170.46
Dividend Yield
2.12%
Astrazeneca stock logo

7. Astrazeneca NYSE:AZN

$166.69 +2.13 (+1.29%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$166.72 +0.03 (+0.02%)
As of 09/25/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Capitalization
$258.35 billion
P/E Ratio
24.92
Consensus Rating
Moderate Buy
Consensus Price Target
$206.67 (+24.0% Upside)
Volume
1.92 million shares
Average Volume
2.91 million shares
Today's Range
$164.60
▼
$166.81
50-Day Range
$155.79
▼
$173.24
52-Week Range
$146.66
▼
$212.71
Dividend Yield
2.61%
Thermo Fisher Scientific stock logo

8. Thermo Fisher Scientific NYSE:TMO

$674.54 -3.85 (-0.57%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$671.94 -2.61 (-0.39%)
As of 09/25/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • Thermo Fisher Scientific Inc. recently reported strong financial performance for the quarter ended July 23, 2026, with earnings per share of $6.03, which exceeded the analyst consensus estimate of $5.71 by $0.32, demonstrating the company's ability to generate profits above market expectations.
  • The company's revenue for the most recent quarter reached $11.99 billion, surpassing the consensus estimate of $11.71 billion and marking a 10.5% year-over-year increase, which indicates robust demand for its life sciences solutions and analytical instruments.
  • Thermo Fisher Scientific Inc. has launched the Gibco CHO-K1 Catalog Panel, a new off-the-shelf media offering for biologics developers that includes cGMP-ready, chemically defined, and animal-origin-free basal and feed media, positioning the company to capture growth in the expanding biologics and biosimilars manufacturing market.

Cons of Thermo Fisher Scientific

  • The current stock price of $679.25 is significantly higher than the average analyst price target of $624.64, which may indicate that the stock is overvalued relative to Wall Street's expectations for its future earnings potential.
  • Company insiders, including CEO Marc N. Casper, have been selling shares recently; for example, Casper sold 275 shares on August 24, 2026, and 10,000 shares on August 20, 2026, which could signal a lack of confidence in the stock's short-term upside or a desire to diversify personal holdings.
  • Thermo Fisher Scientific Inc. has a P/E ratio of 36.54, which is relatively high compared to many other companies in the life sciences sector, suggesting that investors are paying a premium for its growth that may not be justified if future earnings growth slows down.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$249.58 billion
P/E Ratio
36.29
Consensus Rating
Moderate Buy
Consensus Price Target
$628.78 (-6.8% Downside)
Volume
2.10 million shares
Average Volume
2.12 million shares
Today's Range
$664.53
▼
$678.00
50-Day Range
$522.69
▼
$679.25
52-Week Range
$435.27
▼
$682.98
Dividend Yield
0.28%
Amgen stock logo

9. Amgen NASDAQ:AMGN

$414.61 +8.57 (+2.11%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$416.40 +1.79 (+0.43%)
As of 09/25/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. recently reported positive topline results from the Phase 3 OASIZ 301 trial for dazodalibep, a potential first-in-class CD40L antagonist for systemic Sjögren’s disease, which achieved a statistically significant and clinically meaningful improvement in the primary endpoint, suggesting a new revenue driver in a market with no currently approved disease-modifying therapies.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $6.29, which beat the consensus estimate of $5.62 by $0.67, alongside revenue of $10.05 billion that exceeded analyst expectations of $9.43 billion, indicating robust operational execution and demand for its therapeutic portfolio.
  • Amgen Inc. offers a relatively attractive income stream for investors with a dividend yield of 2.46%, supported by a recent quarterly dividend payment of $2.52 per share, which provides a steady cash flow component to the investment despite the stock's growth-oriented profile.

Cons of Amgen

  • Despite the positive trial results, Bank of America maintained an Underperform rating with a price target of $317, citing uncertainty around the dazodalibep data, while Citi also flagged open questions, indicating that some analysts believe the current stock price may not fully reflect the risks associated with the drug's approval and commercialization.
  • The approval filing for dazodalibep is expected to depend on results from another trial, meaning that the potential revenue boost from this new product is not yet secured and remains subject to further regulatory and clinical hurdles, which could delay or diminish its financial impact.
  • Erste Group slightly reduced its FY2027 earnings estimate to $24.36 per share from $24.43, suggesting that near-term earnings expectations have not materially improved despite the pipeline news, which may limit the upside potential for investors seeking immediate earnings growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$224.15 billion
P/E Ratio
25.77
Consensus Rating
Hold
Consensus Price Target
$383.46 (-7.5% Downside)
Volume
2.09 million shares
Average Volume
2.98 million shares
Today's Range
$404.19
▼
$415.20
50-Day Range
$364.17
▼
$444.12
52-Week Range
$269.77
▼
$447.03
Dividend Yield
2.43%
Gilead Sciences stock logo

10. Gilead Sciences NASDAQ:GILD

$150.93 +1.24 (+0.83%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$150.81 -0.12 (-0.08%)
As of 09/25/2026 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The stock is currently trading at $150.93, which is below the consensus price target of $158.78, suggesting potential upside for investors as analysts maintain a Moderate Buy rating.
  • Gilead Sciences, Inc. recently expanded access to its HIV prevention drug lenacapavir across 120 high-incidence countries through royalty-free voluntary licensing, signaling strong global demand and strategic growth in its core virology franchise.
  • The company reported Q2 2026 revenue of $7.80 billion, beating the consensus estimate of $7.40 billion, demonstrating robust top-line growth of 10.6% year-over-year despite a net loss.

Cons of Gilead Sciences

  • Gilead Sciences, Inc. reported a negative earnings per share of ($6.75) in Q2 2026 and a negative net margin of 10.64%, indicating ongoing profitability challenges despite revenue growth.
  • Insiders have sold 105,000 shares valued at $14,616,390 over the last 90 days, including significant sales by CEO Daniel O’Day and CFO Andrew Dickinson, which may signal reduced internal confidence.
  • The company has a debt-to-equity ratio of 2.03, indicating a high level of leverage that could pose financial risks if interest rates remain elevated or if cash flows are disrupted.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$187.15 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$158.78 (+5.2% Upside)
Volume
5.28 million shares
Average Volume
5.70 million shares
Today's Range
$148.02
▼
$151.00
50-Day Range
$129.31
▼
$152.67
52-Week Range
$108.46
▼
$157.29
Dividend Yield
2.17%
Abbott Laboratories stock logo

11. Abbott Laboratories NYSE:ABT

$101.33 +0.26 (+0.26%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$101.26 -0.07 (-0.07%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • Abbott Laboratories recently announced an exclusive partnership with Berry Street that combines the company's Lingo over-the-counter continuous glucose monitor with Berry Street's insurance-covered registered-dietitian and nutrition-coaching platform, a move that could improve Lingo adoption, expand Abbott's consumer health ecosystem, and strengthen its position in metabolic-health services.
  • The company's Volt Pulsed Field Ablation System reportedly saw its first clinical use in Canada and at an Illinois heart center for treating atrial fibrillation, and additional real-world use could support the medical-device pipeline and future cardiovascular revenue growth.
  • Abbott Laboratories reported $1.31 earnings per share for the quarter ended July 16th, topping the consensus estimate of $1.28 by $0.03, while the firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion, with revenue up 13.0% compared to the same quarter last year.

Cons of Abbott Laboratories

  • Abbott agreed to pay approximately $385 million to settle infant-formula litigation, and although the settlement removes some legal uncertainty, the cash cost and reputational overhang are negative for near-term sentiment.
  • Valuation comparisons with faster-growing healthcare companies, including Exact Sciences, may reduce enthusiasm among growth-oriented investors, as Abbott's P/E ratio of 32.79 is higher than some peers.
  • QRG Capital Management Inc. decreased its stake in shares of Abbott Laboratories by 28.7% during the second quarter, selling 83,416 shares, and Envestnet Asset Management Inc. trimmed its position by 23.7% in the 2nd quarter, selling 1,228,773 shares, indicating some institutional investors are reducing their exposure.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$175.27 billion
P/E Ratio
32.79
Consensus Rating
Moderate Buy
Consensus Price Target
$119.50 (+17.9% Upside)
Volume
7.77 million shares
Average Volume
8.42 million shares
Today's Range
$100.09
▼
$101.82
50-Day Range
$99.67
▼
$116.70
52-Week Range
$81.97
▼
$135.45
Dividend Yield
2.49%
Novo Nordisk A/S stock logo

12. Novo Nordisk A/S NYSE:NVO

$38.81 +0.19 (+0.50%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$38.80 -0.02 (-0.04%)
As of 09/25/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Novo Nordisk's stock is currently trading at $38.61, which is significantly below its 52-week high of $64.16, offering a potential entry point for investors who believe the market has overreacted to recent negative sentiment.
  • The company's investigational once-weekly drug, CagriSema, demonstrated superior weight loss results compared to Eli Lilly's tirzepatide in the REIMAGINE 5 trial, including approximately 21% weight loss in obesity, positioning it as a strong future competitor to Zepbound.
  • Novo Nordisk is diversifying its pipeline beyond GLP-1 drugs, with Frehemgo and Sogroya receiving positive opinions from European regulators and Singapore approving Wegovy for certain liver-related conditions, reducing reliance on a single therapeutic area.

Cons of Novo Nordisk A/S

  • Investors were underwhelmed by the company's long-term strategy, as the $23 billion risk-adjusted pipeline target did not sufficiently reassure the market that growth can withstand slowing GLP-1 momentum and semaglutide's approaching patent cliff.
  • Competitive pressure remains intense, with Eli Lilly leading Novo in GLP-1 market share and investor sentiment, while Viking Therapeutics' positive maintenance data highlights the threat from emerging drugs with less frequent dosing.
  • The stock has experienced significant volatility, including an 8% drop following CEO warnings about risks facing Wegovy and Ozempic, and is on track for its worst week in over six months, reflecting heightened investor uncertainty.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$173.24 billion
P/E Ratio
9.49
Consensus Rating
Hold
Consensus Price Target
$64.94 (+67.3% Upside)
Volume
9.92 million shares
Average Volume
12.76 million shares
Today's Range
$38.41
▼
$38.83
50-Day Range
$38.19
▼
$51.56
52-Week Range
$35.12
▼
$64.16
Dividend Yield
2.10%
Pfizer stock logo

13. Pfizer NYSE:PFE

$28.68 +0.27 (+0.93%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$28.67 0.00 (-0.02%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. offers a high dividend yield of 6.16%, which is attractive for income-focused investors seeking regular cash flow from their portfolio holdings.
  • The FDA recently approved the 2026-2027 COMIRNATY XFG vaccine formula, providing a new source of seasonal revenue and supporting the company's infectious disease portfolio.
  • Pfizer Inc. completed a Phase 3 study in Japan for its RSVpreF vaccine, which could expand its market opportunity in adult RSV prevention and diversify its vaccine revenue streams.

Cons of Pfizer

  • Pfizer Inc.'s COVID-19 related products continue to decline in revenue, and overall company revenue has been broadly flat, raising concerns about future growth prospects.
  • The high dividend yield of 6.16% raises questions about payout sustainability, as some analysts note an unfavorable payout ratio that could be at risk if earnings weaken.
  • Analysts remain divided on Pfizer Inc.'s valuation, with some arguing the stock may already reflect benefits from overseas pricing agreements, suggesting limited upside potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$163.41 billion
P/E Ratio
37.73
Consensus Rating
Hold
Consensus Price Target
$28.39 (-1.0% Downside)
Volume
27.75 million shares
Average Volume
32.25 million shares
Today's Range
$28.17
▼
$28.69
50-Day Range
$24.53
▼
$29.02
52-Week Range
$23.61
▼
$29.21
Dividend Yield
6.00%
Danaher stock logo

14. Danaher NYSE:DHR

$224.65 +0.88 (+0.39%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$222.50 -2.15 (-0.96%)
As of 09/25/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Recent analyst sentiment has turned strongly positive, with The Goldman Sachs Group raising its price target from $210.00 to $250.00 and assigning a "buy" rating, suggesting significant upside potential from the current stock price of $224.65.
  • The company demonstrated strong financial performance in its most recent earnings report on July 20, 2026, beating consensus estimates with an actual EPS of $1.94 compared to the expected $1.85, while also exceeding revenue forecasts with $6.265 billion in sales against a consensus of $6.121 billion.
  • Danaher Co. maintains a consistent track record of outperforming market expectations, having beaten EPS consensus in the last four reported quarters, including a 4.2% beat in Q1 2026 and a 9.9% beat in Q2 2026, indicating reliable operational execution.

Cons of Danaher

  • The stock is trading at a premium valuation with a P/E ratio of 39.90, which is significantly higher than the market average, potentially leaving little room for error if growth slows or if the stock reverts to its mean.
  • Despite recent gains, the stock is still trading below its 52-week high of $242.80 and has experienced significant volatility, including a gap down of over 32 points in July 2026, indicating sensitivity to market sentiment and potential for sharp corrections.
  • Short interest has been fluctuating and remains a notable factor, with 8.34 million shares shorted as of September 15, 2026, representing about 1.33% of the float, which could lead to selling pressure if bearish sentiment gains traction.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$157.81 billion
P/E Ratio
39.90
Consensus Rating
Moderate Buy
Consensus Price Target
$230.23 (+2.5% Upside)
Volume
4.42 million shares
Average Volume
3.85 million shares
Today's Range
$221.60
▼
$224.90
50-Day Range
$179.01
▼
$224.65
52-Week Range
$160.93
▼
$242.80
Dividend Yield
0.71%
Intuitive Surgical stock logo

15. Intuitive Surgical NASDAQ:ISRG

$405.18 +5.66 (+1.42%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$405.66 +0.48 (+0.12%)
As of 09/25/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • Intuitive Surgical, Inc. recently received CE mark approval for using its da Vinci SP single-port robotic system in transvaginal gynecologic procedures, a world's-first indication that broadens its clinically supported use in complex anatomical spaces and deepens its position in minimally invasive, scarless surgery.
  • The company is expanding robotic surgery into ambulatory surgery centers with lower-cost XiR systems, which opens access to new customers and outpatient procedures, creating a new growth engine beyond traditional hospital settings.
  • Intuitive Surgical, Inc. reported strong second-quarter results with revenue of $2.89 billion, beating analyst expectations of $2.83 billion, and earnings per share of $2.80, which exceeded the consensus estimate of $2.48, demonstrating robust demand and operational efficiency.

Cons of Intuitive Surgical

  • Intuitive Surgical, Inc. stock has declined sharply this year, with a 29% drop, underperforming the S&P 500 which returned 16.5% over the same period, reflecting market concerns about moderating U.S. procedure growth and valuation pressures.
  • Several major brokerages have recently lowered their price targets, including Stifel Nicolaus cutting from $670 to $550, Wells Fargo reducing from $654 to $487, and Leerink Partners dropping from $573 to $454, signaling a more cautious outlook on the company's future earnings potential.
  • Insider selling has been notable, with executives such as Gary Loeb and Gary Guthart selling shares in August 2026, and insiders collectively selling 12,370 shares worth approximately $4.89 million in the last ninety days, which may indicate reduced confidence from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$143.14 billion
P/E Ratio
46.41
Consensus Rating
Moderate Buy
Consensus Price Target
$508.68 (+25.5% Upside)
Volume
2.50 million shares
Average Volume
2.32 million shares
Today's Range
$391.92
▼
$406.39
50-Day Range
$332.02
▼
$405.18
52-Week Range
$328.57
▼
$603.88
Dividend Yield
N/A
Vertex Pharmaceuticals stock logo

16. Vertex Pharmaceuticals NASDAQ:VRTX

$526.19 +3.81 (+0.73%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$523.65 -2.54 (-0.48%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease, a significant expansion beyond its core cystic fibrosis business that has attracted analyst attention and suggests new growth engines in the kidney disease sector.
  • The stock is currently trading at $526.19, which is below the consensus price target of $573.83 from analysts who maintain a Moderate Buy rating, indicating potential upside as the market digests recent clinical successes and pipeline diversification.
  • Vertex Pharmaceuticals Incorporated demonstrated strong financial performance in the most recent quarter with revenue of $3.33 billion, exceeding analyst estimates of $3.23 billion and representing a 12.5% year-over-year increase, highlighting robust commercial execution.

Cons of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated recently missed its earnings per share consensus estimate by $0.01 in the latest quarter, reporting $4.73 against an expected $4.74, which may signal challenges in maintaining consistent profitability growth despite revenue beats.
  • There has been significant insider selling activity, with multiple executives including the CMO and EVPs selling shares in recent months, such as Carmen Bozic selling over 10,000 shares in May and June 2026, which can be interpreted as a lack of confidence in near-term stock appreciation.
  • The company's price-to-earnings ratio stands at 30.63, which is relatively high and may limit upside potential if growth slows, especially given that the stock has already risen significantly from its 52-week low of $379.72 to its current level.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$133.55 billion
P/E Ratio
30.63
Consensus Rating
Moderate Buy
Consensus Price Target
$573.83 (+9.1% Upside)
Volume
754,282 shares
Average Volume
994,184 shares
Today's Range
$518.92
▼
$527.69
50-Day Range
$470.72
▼
$557.96
52-Week Range
$379.72
▼
$560.25
Dividend Yield
N/A
Bristol Myers Squibb stock logo

17. Bristol Myers Squibb NYSE:BMY

$62.84 +1.34 (+2.19%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$62.84 0.00 (-0.01%)
As of 09/25/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • Bristol-Myers Squibb was recently upgraded from a hold to a strong-buy rating by Zacks Research, which also raised its earnings estimates for the company, including full-year 2027 EPS to $6.24 and full-year 2028 EPS to $5.23, signaling improved confidence in the company's future financial performance.
  • The stock currently trades at $62.84, which is below the consensus price target of $67.06, suggesting potential upside for investors as the current price is lower than what analysts on average expect the stock to reach.
  • Bristol-Myers Squibb offers a dividend yield of 4.05%, providing a steady income stream for investors, which is particularly attractive in a market where income-focused strategies are gaining popularity.

Cons of Bristol Myers Squibb

  • Despite recent positive developments, investors remain concerned about patent expirations and declines in established blockbuster products, which could negatively impact the company's revenue and earnings in the long term.
  • The company's debt-to-equity ratio is 1.89, indicating a relatively high level of debt compared to its equity, which could pose financial risks if interest rates rise or if the company faces unexpected expenses.
  • Bristol-Myers Squibb's revenue growth has been modest, with a year-over-year increase of 5.7% in the most recent quarter, which may not be sufficient to offset the impact of declining sales from mature products.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$128.41 billion
P/E Ratio
13.84
Consensus Rating
Moderate Buy
Consensus Price Target
$67.06 (+6.7% Upside)
Volume
10.03 million shares
Average Volume
10.35 million shares
Today's Range
$61.40
▼
$62.91
50-Day Range
$60.30
▼
$68.06
52-Week Range
$42.52
▼
$68.64
Dividend Yield
4.01%
CVS Health stock logo

18. CVS Health NYSE:CVS

$89.16 +4.11 (+4.83%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$89.16 +0.01 (+0.01%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported second-quarter earnings that significantly exceeded market expectations, with actual earnings per share of $2.58 compared to a consensus estimate of $1.87, demonstrating strong operational execution and profitability that supports the stock's current price of $89.16.
  • The company has received a "Moderate Buy" consensus rating from twenty-two research analysts, with an average price target of $107.24, indicating that Wall Street believes the stock is undervalued relative to its fundamental performance and growth potential.
  • CVS Health Co. offers a dividend yield of 3.13%, providing a steady income stream for investors, supported by a payout ratio of 70.37% which suggests the company is managing its cash flow to maintain shareholder returns while investing in its business.

Cons of CVS Health

  • Proposed Medicare restrictions on remote patient monitoring could reduce reimbursement or utilization for CVS Health Co., creating uncertainty about the business's outlook and potentially impacting revenue from its Health Services segment.
  • Insider selling activity has been notable, with Director Larry Robbins selling over 3.3 million shares in May 2026, which may signal a lack of confidence from company insiders in the stock's near-term performance.
  • The company's debt-to-equity ratio of 0.74 and current ratio of 0.87 indicate a moderate level of financial leverage and liquidity constraints, which could limit its flexibility in responding to economic downturns or increased interest rates.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$113.99 billion
P/E Ratio
23.59
Consensus Rating
Moderate Buy
Consensus Price Target
$107.24 (+20.3% Upside)
Volume
15.77 million shares
Average Volume
7.39 million shares
Today's Range
$84.70
▼
$89.35
50-Day Range
$84.96
▼
$110.40
52-Week Range
$69.51
▼
$110.68
Dividend Yield
2.98%
Medtronic stock logo

19. Medtronic NYSE:MDT

$88.47 -0.04 (-0.05%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$88.29 -0.18 (-0.20%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc recently announced a $700 million strategic partnership with Cornerstone Robotics to distribute the Sentire surgical system alongside its proprietary Hugo robotic-assisted surgery system in Europe, China, and Singapore, positioning the company to capture growth in the rapidly expanding medical robotics market which is projected to grow from $20.6 billion in 2026 to $41.7 billion by 2031.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $1.45 which beat analyst estimates of $1.39, while revenue reached $9.76 billion, exceeding expectations of $9.55 billion and representing a 13.7% year-over-year increase, indicating accelerating growth momentum.
  • Medtronic plc offers a compelling income opportunity with a current dividend yield of 3.25%, supported by a recent quarterly dividend announcement of $0.72 per share payable on October 16th, which provides a steady cash flow for income-focused investors.

Cons of Medtronic

  • Medtronic plc is currently trading at $88.47, which is significantly below its 52-week high of $106.33, reflecting a substantial decline in value over the past year that may indicate ongoing market skepticism about the company's growth trajectory or valuation.
  • Recent institutional activity shows mixed signals, with Envestnet Asset Management Inc. decreasing its holdings by 9.4% in the second quarter and QRG Capital Management Inc. cutting its stake by 6.6%, suggesting that some large investors are reducing their exposure to the stock.
  • The company's payout ratio is currently 70.94%, which is relatively high and may limit the amount of free cash flow available for reinvestment in research and development or debt reduction, potentially constraining long-term growth capabilities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$113.38 billion
P/E Ratio
21.79
Consensus Rating
Moderate Buy
Consensus Price Target
$103.92 (+17.5% Upside)
Volume
13.05 million shares
Average Volume
9.63 million shares
Today's Range
$87.12
▼
$88.99
50-Day Range
$82.00
▼
$94.13
52-Week Range
$73.31
▼
$106.33
Dividend Yield
3.25%
Stryker stock logo

20. Stryker NYSE:SYK

$272.11 +2.36 (+0.87%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$272.27 +0.17 (+0.06%)
As of 09/25/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Stryker Co. recently reported strong financial performance in its most recent quarter, beating consensus estimates with earnings per share of $3.69 compared to the expected $3.49, while also achieving revenue of $6.59 billion, which exceeded the $6.58 billion forecast and represented a 9.4% year-over-year increase.
  • The company maintains a favorable valuation profile with a current stock price of $272.11, which is significantly below the consensus price target of $380.40, suggesting substantial potential upside for investors as the stock trades at a P/E ratio of 28.20.
  • Stryker Co. offers a stable income stream through its dividend, which has a yield of 1.28% and a payout ratio of 36.48%, indicating that the company retains a significant portion of its earnings for reinvestment while still providing regular cash returns to shareholders.

Cons of Stryker

  • Stryker Co. is facing legal scrutiny, with Pomerantz LLP and Block & Leviton investigating claims on behalf of investors for potential securities law violations, which could lead to significant financial liabilities and reputational damage.
  • The company disclosed persisting peripheral vascular manufacturing issues that were previously thought to be resolved, causing an 8.8% drop in the stock price on September 8, 2026, and raising concerns about operational execution and product quality.
  • Analysts have recently lowered their price targets for Stryker Co., with Raymond James cutting its target from $370 to $330 and Canaccord Genuity Group reducing its target from $400 to $385, reflecting a more cautious outlook on the company's near-term growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$104.47 billion
P/E Ratio
28.20
Consensus Rating
Moderate Buy
Consensus Price Target
$374.42 (+37.6% Upside)
Volume
2.33 million shares
Average Volume
2.99 million shares
Today's Range
$268.69
▼
$275.84
50-Day Range
$269.98
▼
$352.35
52-Week Range
$267.00
▼
$392.55
Dividend Yield
1.29%
McKesson stock logo

21. McKesson NYSE:MCK

$866.56 -2.80 (-0.32%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$866.56 0.00 (0.00%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • McKesson Co. recently reported first-quarter fiscal 2027 results where it beat consensus estimates, posting earnings per share of $9.93 against an expected $9.56 and generating revenue of $105.38 billion, which exceeded the $103.88 billion forecast and represented a 7.7% year-over-year increase.
  • The company has strengthened its financial outlook by raising its full-year fiscal 2027 adjusted earnings per share guidance to a range of $44.20 to $45.00, a move that analysts suggest supports the current valuation and indicates confidence in continued operational expansion.
  • Wall Street maintains a positive stance on the stock, with a consensus rating of Moderate Buy and an average price target of $973.44, which implies significant upside potential from the current stock price of $866.56.

Cons of McKesson

  • McKesson Co. is currently navigating a confirmed cyberattack that has resulted in data theft affecting oncology and multispecialty customers, creating potential legal, operational, and reputational risks that could impact future earnings.
  • Corporate insiders have been net sellers recently, with CEO Brian Tyler selling 8,463 shares in July 2026 and Director Bradley Lerman selling 301 shares in August 2026, which may signal a lack of confidence in the stock's near-term performance.
  • The company's negative return on equity of 253.21% in the most recent quarter, despite positive net margins, suggests significant leverage or accounting complexities that may concern value-focused investors regarding the efficiency of capital deployment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$101.04 billion
P/E Ratio
23.19
Consensus Rating
Moderate Buy
Consensus Price Target
$973.44 (+12.3% Upside)
Volume
452,038 shares
Average Volume
886,860 shares
Today's Range
$858.76
▼
$871.00
50-Day Range
$813.95
▼
$927.16
52-Week Range
$723.68
▼
$999.00
Dividend Yield
0.43%
Sanofi stock logo

22. Sanofi NASDAQ:SNY

$41.11 +0.17 (+0.42%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$41.38 +0.27 (+0.64%)
As of 09/25/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi is actively broadening its business development strategy to mitigate future risks, with new leadership describing the company as "phase agnostic" in its search for external opportunities. This means the firm is no longer limited to early-stage assets but is now evaluating deals across all development stages, including late-stage programs, to ensure strategic fit and financial return. This approach allows Sanofi to potentially acquire established products that can immediately contribute to revenue, helping to offset the upcoming loss of exclusivity for its flagship drug, Dupixent, in the early part of the next decade.
  • The company is undergoing a significant strategic review of its late-stage pipeline under new Chief Scientific Officer Mike Quigley, who has emphasized a mindset of "quicker decision-making, transparency, and underpromise, overdeliver." This rigorous assessment of scientific rigor and capital allocation aims to streamline the research and development process, potentially reducing the time to market for new therapies and improving the overall efficiency of the company's innovation engine, which is a key driver for long-term shareholder value.
  • Sanofi has secured a new strategic partnership with Cheplapharm, acquiring a 26.4% stake in the company to strengthen its position in mature medicines. This move is significant because it provides Sanofi with a robust distribution and commercialization platform for its established products, ensuring continued market presence and revenue stability even as the company focuses its R&D resources on next-generation therapies and specialty care areas like immunology and rare diseases.

Cons of Sanofi

  • Sanofi faces significant headwinds from the upcoming loss of exclusivity for Dupixent, its most profitable drug, in the early part of the next decade. This event is expected to erode a substantial portion of the company's revenue, and while management is working to mitigate this through new drug launches and acquisitions, the scale of the revenue loss poses a serious risk to future earnings growth and could pressure the stock price if the company fails to replace this revenue stream with equally profitable products.
  • The company has recently terminated several late-stage drug candidates, including amlitelimab, itepekimab, and belantamab, which signals a challenging environment for its R&D pipeline. These terminations not only represent a loss of potential future revenue but also raise questions about the scientific rigor and success rate of Sanofi's drug development process. Investors may be concerned that further pipeline setbacks could undermine the company's ability to deliver new growth drivers in the near term.
  • Sanofi's stock has been trading at or near its 52-week low, with a recent close of $41.11, indicating persistent downward pressure from the market. This sustained decline suggests that investors are skeptical about the company's ability to execute its strategic plans and generate future growth. The stock's position near its 52-week low also reflects a lack of confidence in the company's near-term prospects, which could deter new investors and limit upside potential in the short term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$99.67 billion
P/E Ratio
21.52
Consensus Rating
Hold
Consensus Price Target
$49.50 (+20.4% Upside)
Volume
2.22 million shares
Average Volume
2.34 million shares
Today's Range
$40.66
▼
$41.12
50-Day Range
$40.94
▼
$46.02
52-Week Range
$40.65
▼
$52.68
Dividend Yield
4.29%
GSK stock logo

23. GSK NYSE:GSK

$49.29 -0.36 (-0.72%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$49.24 -0.06 (-0.12%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc is aggressively expanding its oncology pipeline through recent high-value acquisitions, including a deal with HUTCHMED for HMPL-A830 and a $750 million acquisition of a trispecific T-cell engager from Chimagen Biosciences, which signals a strong strategic pivot toward high-growth cancer treatments under CEO Luke Miels.
  • The company recently increased its quarterly dividend to $0.4515 per share, representing an annualized yield of approximately 3.6%, which provides a reliable income stream for investors and reflects management's confidence in maintaining cash flow despite significant R&D investments.
  • GSK plc demonstrated strong financial performance in its most recent reported quarter, beating consensus estimates with an EPS of $1.36 and revenue of $11.14 billion, while maintaining a high return on equity of 43.23%, indicating efficient capital deployment and robust profitability.

Cons of GSK

  • The consensus rating from eleven brokerages covering the company remains "Hold," with two analysts issuing sell ratings, indicating that the broader market is cautious about the stock's valuation and growth prospects despite recent positive news.
  • Recent labor advocacy efforts to preserve jobs at GSK's Dresden vaccine plant in Germany highlight potential workforce and restructuring concerns, which could lead to execution costs or reputational pressure that may impact operational stability.
  • The company's debt-to-equity ratio stands at 0.81, and its current ratio is 0.82, suggesting that GSK plc may face liquidity challenges or higher financial leverage risks as it funds its aggressive acquisition strategy and R&D pipeline.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$99.60 billion
P/E Ratio
15.41
Consensus Rating
Hold
Consensus Price Target
$56.50 (+14.6% Upside)
Volume
3.29 million shares
Average Volume
2.80 million shares
Today's Range
$49.00
▼
$49.50
50-Day Range
$48.14
▼
$53.78
52-Week Range
$39.46
▼
$61.69
Dividend Yield
3.61%
HCA Healthcare stock logo

24. HCA Healthcare NYSE:HCA

$435.18 +11.70 (+2.76%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$433.12 -2.06 (-0.47%)
As of 09/25/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The stock is currently trading at $435.18, which is below the average analyst price target of $463.70, suggesting potential upside as the consensus rating remains a Moderate Buy from twenty-three ratings firms.
  • HCA Healthcare, Inc. recently reported strong financial performance with 8.7% year-over-year revenue growth and earnings per share of $7.59, which exceeded the consensus estimate of $7.56, demonstrating the company's ability to drive volume growth and manage costs effectively.
  • The company is actively expanding its outpatient network, with a goal to reach 20 outpatient facilities per hospital by 2030, a strategic shift that positions the firm to capture more high-margin care outside of traditional inpatient settings.

Cons of HCA Healthcare

  • Legal and regulatory risks are increasing, as evidenced by a recent investigation by Pomerantz Law Firm on behalf of investors and an antitrust lawsuit against the company that has hit a roadblock, creating potential for future liabilities and reputational damage.
  • Short interest in the stock has been rising, with shares shorted increasing to approximately 6.48 million shares as of September 15, 2026, indicating that a growing number of traders are betting against the stock's future performance.
  • The company faces pressure from a changing service mix, where payer-mix dynamics may squeeze margins despite healthy volume growth, as the shift toward more complex or lower-reimbursed care types can impact overall profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$94.31 billion
P/E Ratio
14.57
Consensus Rating
Moderate Buy
Consensus Price Target
$463.70 (+6.6% Upside)
Volume
1.02 million shares
Average Volume
1.50 million shares
Today's Range
$420.00
▼
$435.78
50-Day Range
$370.55
▼
$438.14
52-Week Range
$353.99
▼
$556.52
Dividend Yield
0.72%
Elevance Health stock logo

25. Elevance Health NYSE:ELV

$396.28 -1.97 (-0.49%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$400.57 +4.29 (+1.08%)
As of 09/25/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$85.90 billion
P/E Ratio
17.61
Consensus Rating
Moderate Buy
Consensus Price Target
$440.90 (+11.3% Upside)
Volume
1.22 million shares
Average Volume
1.19 million shares
Today's Range
$394.69
▼
$405.13
50-Day Range
$375.44
▼
$424.78
52-Week Range
$274.84
▼
$436.24
Dividend Yield
1.74%
Regeneron Pharmaceuticals stock logo

26. Regeneron Pharmaceuticals NASDAQ:REGN

$788.04 -7.98 (-1.00%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$788.02 -0.01 (0.00%)
As of 09/25/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • Regeneron Pharmaceuticals, Inc. recently delivered a significant earnings beat, reporting actual EPS of $14.29 against a consensus estimate of $10.16 for the quarter ended July 30, 2026, while also exceeding revenue expectations with $4.29 billion in sales compared to the $3.82 billion consensus, demonstrating strong fundamental performance.
  • The company's EYLEA HD product is gaining substantial market momentum, representing roughly 60% of the EYLEA franchise net sales in the second quarter and becoming the only innovative brand in its category to gain market share, driven by new label enhancements that allow for every-four-week dosing flexibility.
  • Regeneron Pharmaceuticals, Inc. is currently trading at $801.82, a price point that sits below its 52-week high of $859.34 and aligns closely with the current analyst consensus price target of $800.36, suggesting the stock may be fairly valued relative to its recent performance and institutional support.

Cons of Regeneron Pharmaceuticals

  • Regeneron Pharmaceuticals, Inc. faces ongoing legal risks, as evidenced by a securities fraud lawsuit filed in September 2026 where investors have the opportunity to lead the case, which could result in significant financial liabilities or reputational damage.
  • There is a consistent pattern of insider selling, with multiple directors and executives, including Huda Y Zoghbi and Marion McCourt, selling shares in August and September 2026, which may signal a lack of confidence in the stock's near-term upside from those closest to the company.
  • The company faces increasing competitive pressure in its core markets, specifically from biosimilar competition in the 2-milligram EYLEA market and the eventual biosimilar competition to Keytruda, which could erode the market share of its key products like Libtayo and EYLEA.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$81.13 billion
P/E Ratio
19.48
Consensus Rating
Moderate Buy
Consensus Price Target
$802.18 (+1.8% Upside)
Volume
540,297 shares
Average Volume
672,244 shares
Today's Range
$784.13
▼
$803.87
50-Day Range
$651.18
▼
$852.03
52-Week Range
$541.00
▼
$859.34
Dividend Yield
0.48%
Moderna stock logo

27. Moderna NASDAQ:MRNA

$198.88 +4.06 (+2.08%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$197.82 -1.06 (-0.53%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More about Moderna

Pros of Moderna

  • Moderna, Inc. recently achieved a significant clinical milestone with its personalized cancer vaccine, intismeran autogene, which met key Phase 3 endpoints in high-risk melanoma when used in combination with Keytruda, demonstrating improvements in recurrence-free survival and distant metastasis-free survival. This success validates the company's oncology platform and provides a clear path toward regulatory filings and commercialization, potentially transforming the stock from a pandemic-dependent entity into a diversified biotech leader with substantial long-term growth potential in cancer care.
  • The stock has experienced a dramatic rerating, reaching a current price of $194.82 as of September 24, 2026, which is near its 52-week high of $195.71. This surge, which includes a 177% increase in recent months, reflects strong investor confidence in the company's ability to pivot beyond its legacy COVID-19 business. The momentum is driven by positive market reception of the cancer vaccine data and the broader mRNA platform, suggesting that the market is now valuing the company based on its future pipeline rather than past pandemic revenues.
  • Moderna, Inc. has demonstrated strong revenue growth in recent quarters, with actual revenue of $145 million in the quarter ending July 31, 2026, significantly beating the consensus estimate of $102.9 million. This performance indicates that the company is successfully commercializing its updated 2026-2027 respiratory vaccines, such as those for influenza and respiratory syncytial virus. The ability to generate substantial revenue from these new products provides a near-term commercial support point and reduces reliance on a single product line, enhancing financial stability.

Cons of Moderna

  • Despite the recent stock surge, the consensus rating from analysts remains "Hold" with a median price target of $80.53 as of August 31, 2026, which is significantly lower than the current stock price of $194.82. This large discrepancy suggests that many analysts believe the stock is overvalued relative to its fundamental earnings potential. The negative P/E ratio of -24.38 further indicates that the company is still unprofitable, and the current valuation may not be supported by immediate financial performance, posing a risk of a significant correction if the stock fails to meet higher expectations.
  • Insider selling activity has been consistent and substantial over the past six months, with 15 sales and no purchases reported. Key executives, including President Stephen Hoge and CFO James M Mock, have sold significant portions of their holdings, with Hoge selling over 240,000 shares for an estimated $20.6 million. While insider sales can be attributed to various personal financial reasons, a pattern of selling without corresponding buying can be interpreted as a lack of confidence in the stock's future performance or a desire to lock in gains, which may weigh on investor sentiment and limit upside potential.
  • Moderna, Inc. continues to report negative earnings per share, with an actual EPS of -1.97 in the most recent quarter, although this was slightly better than the consensus estimate of -2.03. The company's inability to achieve profitability means that it is still burning cash, and investors must rely on future revenue growth and cost management to turn a profit. The negative P/E ratio of -24.38 highlights that the stock is priced based on growth expectations rather than current earnings, which can be risky if the company fails to execute on its pipeline or if the market environment becomes less favorable for high-growth biotech stocks.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$79.40 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$76.72 (-61.4% Downside)
Volume
13.90 million shares
Average Volume
14.62 million shares
Today's Range
$192.51
▼
$202.67
50-Day Range
$53.86
▼
$198.88
52-Week Range
$22.28
▼
$202.67
Dividend Yield
N/A
Cigna Group stock logo

28. Cigna Group NYSE:CI

$272.22 +6.72 (+2.53%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$272.39 +0.17 (+0.06%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group recently announced a strategic partnership with OpenAI to support patients with complex conditions, signaling a significant move toward leveraging artificial intelligence to improve care coordination and manage rising healthcare costs.
  • With a current stock price of $265.54, the company trades at a P/E ratio of 10.99, which is notably lower than the broader market average, suggesting the stock may be undervalued relative to its earnings potential and strong financial performance.
  • The company offers a dividend yield of 2.28% with a payout ratio of 25.82%, indicating that the dividend is well-covered by earnings and provides a stable income stream for investors without putting excessive strain on the company's cash flow.

Cons of Cigna Group

  • Insider selling has been significant recently, with CEO David Cordani selling over 200,000 shares in May 2026 and other executives like Nicole Jones and Everett Neville also reducing their positions, which may signal a lack of confidence in the stock's near-term upside.
  • The company faces legal and reputational risks, as evidenced by recent allegations that it ran the clock on a teen's mental health claims, which could lead to increased regulatory scrutiny and potential liabilities in the healthcare sector.
  • Short interest has been increasing, with shares shorted rising to 6.56 million as of September 2026, indicating that a growing number of investors are betting against the stock, which could create downward pressure on the price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$71.88 billion
P/E Ratio
11.26
Consensus Rating
Moderate Buy
Consensus Price Target
$337.10 (+23.8% Upside)
Volume
1.82 million shares
Average Volume
1.42 million shares
Today's Range
$265.35
▼
$273.36
50-Day Range
$265.54
▼
$301.79
52-Week Range
$239.51
▼
$315.47
Dividend Yield
2.29%
Boston Scientific stock logo

29. Boston Scientific NYSE:BSX

$43.88 -0.80 (-1.79%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$43.98 +0.10 (+0.22%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The stock is trading at a significant discount to its historical valuation, currently priced at $43.88, which is near its 52-week low of $42.20. This price represents a substantial drop from its 52-week high of $105.65, suggesting that the market may be overreacting to recent negative news, potentially creating a deep value opportunity for long-term investors who believe in the company's underlying fundamentals.
  • Boston Scientific Co. has demonstrated strong recent financial performance, reporting Q2 2026 earnings per share of $0.86, which exceeded the consensus estimate of $0.83. Additionally, the company reported revenue of $5.44 billion for the quarter, surpassing the consensus estimate of $5.38 billion, with year-over-year revenue growth of 7.5%, indicating that the business is still generating robust sales despite broader market pressures.
  • There is significant insider confidence in the company's future, as CEO Michael F. Mahoney purchased 186,240 shares at an average price of $48.33 in August 2026. This transaction, valued at approximately $9 million, represents a 13.27% increase in his ownership stake, signaling that company leadership believes the current stock price is undervalued relative to its intrinsic worth.

Cons of Boston Scientific

  • The stock has experienced a severe decline, losing more than half of its value from its 52-week high of $105.65 to the current price of $43.88. This significant drop reflects deep market skepticism about the company's future earnings power, and the stock is currently trading below its 50-day simple moving average of $46.96 and its 200-day simple moving average of $52.81, indicating a strong downward trend that may persist.
  • Recent analyst actions have been negative, with Citi downgrading the stock due to increasing competition and the fallout from a cyberattack. Additionally, Boston Scientific Co. was added to the Zacks Rank #5 (Strong Sell) list in September 2026, reflecting a consensus view that the company's near-term outlook is weak and that it may underperform its peers in the healthcare equipment sector.
  • Short interest in the stock has expanded significantly, with shares shorted increasing by 74.4% in August to reach 48,173,758 shares. This high level of short selling indicates that a substantial portion of the market is betting against the stock, and the days-to-cover ratio of 2.35 suggests that it would take over two days of average trading volume to cover all short positions, which can lead to increased volatility and downward pressure on the price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$63.65 billion
P/E Ratio
17.77
Consensus Rating
Moderate Buy
Consensus Price Target
$70.19 (+60.0% Upside)
Volume
15.20 million shares
Average Volume
20.19 million shares
Today's Range
$43.33
▼
$44.84
50-Day Range
$43.00
▼
$52.02
52-Week Range
$42.20
▼
$105.65
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

30. Takeda Pharmaceutical NYSE:TAK

$18.84 +0.26 (+1.37%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$18.54 -0.31 (-1.62%)
As of 09/25/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Takeda Pharmaceutical Company Limited recently demonstrated strong financial performance by beating consensus estimates in its latest quarterly report, posting earnings per share of $0.95 against an expected $0.41 and generating revenue of $7.50 billion compared to the anticipated $7.13 billion, which signals robust operational execution and potential for continued earnings growth.
  • The company has secured significant regulatory and commercial milestones, including U.S. FDA acceptance of its new drug application for zasocitinib under priority review for moderate-to-severe plaque psoriasis and Japan approval for Elahere in ovarian cancer, which expands its therapeutic portfolio and opens new revenue streams in high-demand markets.
  • Strategic partnerships are enhancing global market reach, such as the agreement with Dr. Reddy’s to distribute the Qdenga dengue vaccine in India, which positions Takeda Pharmaceutical Company Limited to capture a substantial share of the emerging market for infectious disease prevention in a high-population region.

Cons of Takeda Pharmaceutical

  • Recent insider activity shows a trend of selling, with multiple executives including Lauren Rusckowski Duprey and Andrew Stewart Plump selling significant blocks of shares in August and September 2026, which may indicate internal concerns about the stock's current valuation or future performance.
  • The company's valuation appears elevated with a P/E ratio of 54.71, which is high relative to many peers in the pharmaceutical sector, potentially limiting upside potential if earnings growth does not accelerate to justify the premium pricing.
  • Short interest has increased slightly in recent months, with shares shorted rising to 4,204,915 as of September 15, 2026, suggesting that some market participants are betting against the stock's price movement, which could create downward pressure.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$60.43 billion
P/E Ratio
55.43
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
2.62 million shares
Average Volume
2.19 million shares
Today's Range
$18.77
▼
$18.91
50-Day Range
$16.58
▼
$19.06
52-Week Range
$12.99
▼
$19.10
Dividend Yield
2.55%
argenex stock logo

31. argenex NASDAQ:ARGX

$959.49 -2.73 (-0.28%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$959.22 -0.27 (-0.03%)
As of 09/25/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • argenx SE recently reported strong second-quarter financial results, with earnings per share of $7.32 significantly exceeding the consensus estimate of $5.86, while revenue of $1.54 billion also surpassed analyst expectations of $1.45 billion, demonstrating robust commercial execution and profitability with a net margin of 32.19%.
  • The stock is currently trading at $959.49, which is below the consensus price target of $1,158.61, suggesting potential upside of approximately 21% as analysts maintain a "Moderate Buy" consensus rating based on the company's strong sales momentum and upcoming clinical data readouts.
  • argenx SE has received recent positive analyst actions, including UBS Group raising its rating from "neutral" to "buy" with a price target of $1,400.00 and Wells Fargo & Company increasing its target to $1,415.00, reflecting confidence in the company's long-term growth trajectory and product franchise strength.

Cons of argenex

  • argenx SE was recently downgraded from a "buy" rating to a "hold" rating by Wall Street Zen, suggesting that some analysts believe the stock's current valuation may not offer sufficient upside potential relative to its risks at this time.
  • The company's price-to-earnings ratio stands at 36.85, which is relatively high compared to broader market averages, indicating that the stock is priced for continued high growth and may be vulnerable to any disappointment in future earnings or revenue performance.
  • Short interest in the stock has been increasing recently, with shares shorted rising to 1,313,174 as of the September 15, 2026 record date, representing a month-to-month increase of 4.27%, which suggests that some market participants are betting against the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$60.03 billion
P/E Ratio
36.85
Consensus Rating
Moderate Buy
Consensus Price Target
$1,158.61 (+20.8% Upside)
Volume
264,372 shares
Average Volume
229,033 shares
Today's Range
$956.24
▼
$967.71
50-Day Range
$830.79
▼
$1,058.90
52-Week Range
$661.85
▼
$1,072.75
Dividend Yield
N/A
Natera stock logo

32. Natera NASDAQ:NTRA

$412.56 +3.77 (+0.92%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$413.15 +0.59 (+0.14%)
As of 09/25/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$59.47 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$336.07 (-18.5% Downside)
Volume
1.61 million shares
Average Volume
1.41 million shares
Today's Range
$407.48
▼
$415.75
50-Day Range
$252.22
▼
$412.56
52-Week Range
$157.43
▼
$415.75
Dividend Yield
N/A
Cencora stock logo

33. Cencora NYSE:COR

$307.12 -2.75 (-0.89%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$305.81 -1.31 (-0.43%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • Management has expressed strong confidence in the company's specialty-focused strategy, specifically in oncology and retina, which is expected to fuel continued growth into fiscal 2027. This strategy is supported by expanded physician-services capabilities and momentum in international businesses, positioning the company to benefit from pharmaceutical innovation and an aging population.
  • Cencora, Inc. recently reported strong fiscal third-quarter results with revenue rising 5.1% to $84.8 billion and adjusted earnings per share climbing 12.0% to $4.48. The company also raised its full-year adjusted EPS outlook to a range of $17.75 to $17.95, signaling robust financial performance and operational efficiency.
  • The company is actively returning capital to shareholders, having repurchased $1 billion of shares in the third quarter and repaid the $800 million term loan related to the Retina Consultants of America acquisition. This aggressive capital allocation strategy, combined with a commitment to growing dividends with earnings, supports shareholder value.

Cons of Cencora

  • The stock is currently trading at $309.53, which is significantly below its 52-week high of $377.54. This price action reflects a period of volatility and potential market skepticism, as the stock also recently hit a 52-week low of $244.82 in May 2026, indicating substantial price swings and risk.
  • There is a reported volume move outside of Cencora, Inc. under its relationship with Walgreens, which became effective July 1. Although executives stated the vast majority of the business remains under the primary contract, this shift will have a wraparound impact on the remaining three quarters of fiscal 2027, potentially affecting revenue and margins.
  • Prescription utilization trends, which were elevated in 2025, faced pressure during January and February of the current fiscal year. Although utilization rebounded in March, this initial dip highlights the sensitivity of the company's core business to changes in prescription volume and market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$58.57 billion
P/E Ratio
22.82
Consensus Rating
Moderate Buy
Consensus Price Target
$370.85 (+20.7% Upside)
Volume
1.04 million shares
Average Volume
1.22 million shares
Today's Range
$304.31
▼
$310.89
50-Day Range
$300.90
▼
$336.98
52-Week Range
$244.82
▼
$377.54
Dividend Yield
0.78%
Cardinal Health stock logo

34. Cardinal Health NYSE:CAH

$220.12 -2.50 (-1.12%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$220.87 +0.75 (+0.34%)
As of 09/25/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Cardinal Health, Inc. recently reported strong earnings results on August 11, 2026, beating analyst expectations with an EPS of $2.91 compared to the consensus estimate of $2.42, demonstrating the company's ability to outperform market forecasts and drive shareholder value through operational efficiency.
  • The stock currently trades at $220.12, which is below the average analyst price target of $266.56, suggesting significant upside potential as the consensus rating remains a Moderate Buy with 16 analysts issuing Buy ratings versus only three Hold ratings.
  • Management has set fiscal 2027 guidance for EPS between $12.40 and $12.60, which exceeds the consensus estimate of $12.05, indicating that the company expects continued double-digit earnings growth across its five operating segments as specialty momentum builds.

Cons of Cardinal Health

  • Corporate insiders have been selling shares recently, with CEO Deborah Weitzman selling 7,354 shares and CAO Mary C. Scherer selling 2,302 shares in August 2026, which may signal that company leadership is taking advantage of higher stock prices to reduce their personal exposure.
  • The company's net margin is only 0.67% and it reported a negative return on equity of 98.53% in the most recent quarter, indicating that while revenue is growing, the company is struggling to convert that top-line growth into substantial bottom-line profitability and efficient use of shareholder capital.
  • Cardinal Health, Inc. faces regulatory risks from Inflation Reduction Act (IRA) pricing changes, which management expects will pressure pharmaceutical revenues, potentially impacting the company's ability to maintain its current margin levels despite efforts to protect profitability through distribution agreements.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.99 billion
P/E Ratio
30.45
Consensus Rating
Moderate Buy
Consensus Price Target
$266.56 (+21.1% Upside)
Volume
2.09 million shares
Average Volume
1.73 million shares
Today's Range
$219.10
▼
$223.02
50-Day Range
$220.12
▼
$248.88
52-Week Range
$149.60
▼
$258.30
Dividend Yield
0.93%
Becton, Dickinson and Company stock logo

35. Becton, Dickinson and Company NYSE:BDX

$183.51 +4.28 (+2.39%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$184.41 +0.90 (+0.49%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • Becton, Dickinson and Company recently deployed the BD Vmax 160, a next-generation pharmacy automation robot, at Fairview Health Services, marking the first U.S. deployment of this technology to manage complex specialty therapies and refrigerated medications, which positions the company at the forefront of intelligent pharmacy automation.
  • The company reported strong second-quarter results with earnings per share of $3.23, beating analyst estimates of $3.14, and revenue of $4.98 billion, which exceeded the consensus estimate of $4.89 billion, demonstrating robust operational performance and top-line growth of 5.4% year-over-year.
  • With a current stock price of $179.45, Becton, Dickinson and Company offers a dividend yield of 2.30%, providing a steady income stream for investors, supported by a recent quarterly dividend of $1.05 per share paid to investors of record on September 9, 2026.

Cons of Becton, Dickinson and Company

  • The stock carries a high price-to-earnings ratio of 54.05, which is significantly above the market average, suggesting that the current valuation may be stretched relative to its earnings power and could limit upside potential if growth slows.
  • Recent insider activity has been predominantly negative, with executives including CEO Thomas E Polen Jr. and EVP Michael Feld selling shares in August 2026, with Polen selling 4,152 shares at an average price of $185.00, which may signal a lack of confidence in near-term stock performance.
  • The company faces fresh regulatory and legal challenges, as indicated by recent reports of SEC and litigation pressure, which could result in additional costs, operational disruptions, or reputational damage that may impact future earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.65 billion
P/E Ratio
55.27
Consensus Rating
Hold
Consensus Price Target
$187.67 (+2.3% Upside)
Volume
1.46 million shares
Average Volume
1.76 million shares
Today's Range
$177.87
▼
$183.92
50-Day Range
$153.17
▼
$191.95
52-Week Range
$127.59
▼
$193.07
Dividend Yield
2.28%
Edwards Lifesciences stock logo

36. Edwards Lifesciences NYSE:EW

$86.40 +0.67 (+0.78%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$85.50 -0.89 (-1.03%)
As of 09/25/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • Recent institutional activity indicates strong confidence in the company's future, as evidenced by Andra AP fonden boosting its stake by 49.0% in the second quarter and Nykredit A S establishing a new position of 212,551 shares, suggesting that large investors are accumulating shares ahead of potential growth.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $0.78, which beat analyst estimates of $0.74, while revenue of $1.74 billion exceeded expectations and grew 13.6% year-over-year, indicating robust demand for its structural heart disease therapies.
  • Edwards Lifesciences Co. has a consensus rating of Moderate Buy with an average price target of $100.27, which represents a significant upside potential from the current stock price of $85.71, reflecting analyst optimism about the company's valuation and future earnings trajectory.

Cons of Edwards Lifesciences

  • The stock is trading at a high price-to-earnings ratio of 49.26, which is significantly above the broader market average, meaning investors are paying a premium for earnings that may not be sustainable if growth slows or if the company faces increased competition in the structural heart disease space.
  • There is a notable pattern of insider selling, with multiple vice presidents and the CFO executing sales of thousands of shares in recent months, such as VP Donald E Bobo Jr. selling 23,145 shares in May and CFO Scott B Ullem selling 13,000 shares in April, which can signal a lack of confidence from those closest to the company's operations.
  • Short interest has been increasing, with shares shorted rising to 9,088,401 in the most recent reporting period, indicating that a portion of the market is betting against the stock's performance, which could lead to volatility if the company fails to meet its aggressive growth targets.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.69 billion
P/E Ratio
49.65
Consensus Rating
Moderate Buy
Consensus Price Target
$100.27 (+16.1% Upside)
Volume
3.60 million shares
Average Volume
3.20 million shares
Today's Range
$84.93
▼
$87.11
50-Day Range
$82.67
▼
$93.59
52-Week Range
$72.30
▼
$96.29
Dividend Yield
N/A
Agilent Technologies stock logo

37. Agilent Technologies NYSE:A

$172.60 -0.24 (-0.14%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$171.50 -1.10 (-0.64%)
As of 09/25/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. shares are currently trading at $173.01, a price that reflects strong recent momentum and a significant increase from the previous close of $165.32, indicating that the market is actively rewarding the company for its recent performance and upward trajectory.
  • The company demonstrated strong financial health in its most recent quarter by reporting revenue of $1.88 billion, which represented an 8.1% year-over-year increase and exceeded analyst expectations of $1.84 billion, while also beating earnings per share estimates with a result of $1.62 compared to the consensus of $1.49.
  • Management has signaled continued growth momentum by raising its full-year fiscal 2026 guidance, with non-GAAP earnings per share now projected between $6.18 and $6.21, which is higher than the previous consensus estimate of $6.06, suggesting that the company expects to maintain its positive trajectory through the end of the year.

Cons of Agilent Technologies

  • The company's current price-to-earnings ratio of 34.06 is relatively high, which may indicate that the stock is overvalued relative to its earnings, potentially limiting the upside potential for new investors entering at the current price of $173.01.
  • Recent insider activity has been negative, with Director Mikael Dolsten selling 634 shares on September 4, 2026, and CEO Padraig McDonnell selling a total of 13,401 shares in November 2025, which could signal a lack of confidence from company leadership in the current stock price.
  • Short interest in the stock has increased in recent months, with shares shorted rising to 5,078,629 as of September 15, 2026, up from 4,824,122 in late April, suggesting that some investors are betting against the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.71 billion
P/E Ratio
33.98
Consensus Rating
Moderate Buy
Consensus Price Target
$170.33 (-1.3% Downside)
Volume
2.58 million shares
Average Volume
2.42 million shares
Today's Range
$169.43
▼
$172.94
50-Day Range
$130.55
▼
$173.01
52-Week Range
$108.35
▼
$174.77
Dividend Yield
0.59%
Humana stock logo

38. Humana NYSE:HUM

$397.09 +16.77 (+4.41%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$399.61 +2.51 (+0.63%)
As of 09/25/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • Humana Inc. recently demonstrated strong financial performance by beating consensus estimates in its most recent quarterly report, posting earnings per share of $7.61 against an expected $7.27 and generating revenue of $40.89 billion, which represented a 26.2% year-over-year increase. This ability to exceed analyst expectations on both the top and bottom lines suggests the company is effectively managing its operations and capturing market share, providing a solid fundamental basis for investor confidence.
  • The stock has experienced a significant recovery, with the current price of $373.54 representing a substantial gain from its 52-week low of $163.11. This upward trajectory indicates that the market is increasingly valuing the company's turnaround efforts and operational improvements, potentially offering investors who entered during the lower price range a significant capital appreciation opportunity as the stock continues to trend toward its 52-week high of $428.88.
  • Humana Inc. offers a stable income stream for investors through its dividend, which currently yields approximately 0.94%. With a payout ratio of 33.49%, the company is distributing a portion of its earnings to shareholders while retaining enough capital for growth, making it an attractive option for those seeking a balance between income generation and potential capital gains in the healthcare sector.

Cons of Humana

  • Despite the recent stock price recovery, the consensus recommendation from thirty ratings firms remains a "Hold," with an average price target of $403.91. This suggests that while the stock has risen, many analysts believe the current price of $373.54 may already reflect much of the positive news, leaving limited upside potential for new investors compared to the broader market or other healthcare peers.
  • Humana Inc. is facing regulatory and operational challenges, including a federal watchdog accusation of upcoding in its Medicare Advantage plans alongside UnitedHealthcare. Additionally, the company is dropping plans covering 600,000 members, which could lead to member churn and increased competition for the remaining customer base, potentially impacting future revenue stability and market share.
  • The company's valuation, with a price-to-earnings ratio of 35.34, is relatively high compared to its historical averages and some industry peers. This premium valuation means that investors are paying a higher price for each dollar of earnings, which can be risky if the company fails to sustain its recent earnings growth or if market sentiment shifts negatively toward the healthcare sector.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.78 billion
P/E Ratio
37.57
Consensus Rating
Hold
Consensus Price Target
$408.61 (+2.9% Upside)
Volume
1.94 million shares
Average Volume
932,709 shares
Today's Range
$386.71
▼
$413.57
50-Day Range
$362.31
▼
$408.79
52-Week Range
$163.11
▼
$428.88
Dividend Yield
0.89%
Teva Pharmaceutical Industries stock logo

39. Teva Pharmaceutical Industries NYSE:TEVA

$39.15 -1.07 (-2.67%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$39.25 +0.10 (+0.26%)
As of 09/25/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$45.67 billion
P/E Ratio
65.25
Consensus Rating
Moderate Buy
Consensus Price Target
$43.73 (+11.7% Upside)
Volume
3.87 million shares
Average Volume
4.91 million shares
Today's Range
$38.93
▼
$40.25
50-Day Range
$30.19
▼
$40.18
52-Week Range
$18.27
▼
$40.79
Dividend Yield
N/A
Medline stock logo

40. Medline NASDAQ:MDLN

$34.70 +0.04 (+0.12%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$34.50 -0.20 (-0.58%)
As of 09/25/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Our mission is to make healthcare run better by delivering improved clinical, financial, and operational outcomes. We are the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care, based on total net sales of med-surg products. We deliver mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. Through our two segments, Medline Brand and Supply Chain Solutions, we offer approximately 335,000 med-surg products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. We hold the leading position across several of our end markets and many of our key product families. We distribute these products through our expansive network of 69 global distribution facilities, spanning over 29 million square feet of warehouse space, and our owned fleet of over 2,000 MedTrans trucks, enabling us to provide next-day delivery to 95% of our U.S. customers. Our integrated business model and customer-centric culture drives lower costs and better value for our stakeholders. This is the foundation for our durable recurring revenue base, with our net sales having grown every year since inception of the Company at a compound annual growth rate (“CAGR”) of 18%. --- We were founded in 1966 as a med-surg product manufacturer serving the hospital and nursing home sites of care. Through our deep engagement with customers, we recognized a significant gap in the market—our customers were underserved by a fragmented supplier base and faced challenges navigating a complex supply chain. We identified their need for a supply chain partner that was fully integrated, cost-effective, high-quality, and resilient. Our vision was to create a differentiated model that solved these pain points through an integrated company that combined both manufacturing and distribution capabilities and would become a trusted partner to our customers. Twenty-eight years ago, we began augmenting our platform to bring this vision to life: we invested in our distribution capabilities, continued to expand our product portfolio, and adopted the Prime Vendor model. This enabled us to serve a more diverse customer base across multiple end markets, while lowering costs and delivering superior service levels. As a result, Medline is now the largest provider of med-surg products and supply chain solutions serving all points of care, based on total net sales of med-surg products. The combination of our expansive product portfolio and our differentiated supply chain creates a force multiplier for our business. Our Medline Brand segment offers approximately 190,000 products, including those manufactured in our 33 facilities, as well as those sourced from our more than 500 global partners. Our Supply Chain Solutions segment offers approximately 145,000 third-party products and provides customized supply chain optimization services. Our entire product portfolio across our segments is supported by differentiated logistics capabilities and a dedicated and tenured U.S. commercial team of approximately 3,800 people. These capabilities and our compelling value proposition allow us to serve as a long-term strategic partner to our customers and expand the scope of our relationships over time. Our Prime Vendor relationships demonstrate our role as a trusted partner to our customers. In these relationships, we enter into long-term agreements to act as the consolidated distributor and logistics provider for these customers’ med-surg product needs. These partnerships give us visibility into our customers’ purchasing behaviors and demand dynamics, which allows us to anticipate their needs and deliver industry-leading service levels. As these relationships mature, we believe customers increasingly choose Medline Brand products for their superior value. Our Prime Vendor model is reinforced by the flywheel effect within our business where we drive cost savings for Prime Vendor customers, which, over time, supports incremental purchasing of our Medline Brand products and increases our scale. This dynamic allows us to drive further efficiencies by offering superior or similar quality to third-party products at a more cost-effective price. Due to the higher margin we earn on Medline Brand products compared to sales of comparable third-party products, we are able to reinvest in customer value while increasing our profitability. --- Since our founding, we have invested in building a unique customer-centric culture with an entrepreneurial spirit. Our employees are committed to deeply understanding how our customers operate, what challenges they face, and how Medline can better support them. They also understand that relationships are rooted in trust and that we must earn the right to serve our customers every day. We focus on problem solving across the continuum of care and we deploy a team of dedicated customer success representatives to learn the complex needs of our customers. Our creative and collaborative culture consistently earns Medline recognition as a preferred employer, including Newsweek’s Greatest Workplaces, Forbes’ America’s Best Large Employers, and a Chicago Tribune Top Workplace. We have grown our net sales every year by retaining existing customers while gaining share with new and existing customers, with CAGRs of 18% since our founding and approximately 14% over the past 10 years. Notably, nearly 90% of our growth during the past 10 years has been organic. Our product portfolio predominantly consists of consumables, such that approximately 90% of our Medline Brand net sales were recurring for the year ended December 31, 2024. Our business is uniquely resilient during market downturns, as evidenced by our growth through every recession since our founding and during global healthcare crises. For example, our net sales grew at approximately 17% during the 2008-2009 financial crisis and at approximately 11% CAGR during the 2020-2022 COVID-19 pandemic. Not only does our business have a strong track record of results, but we also see significant runway for future sales and earnings growth. We are positioned to grow with our customers as healthcare utilization increases, as they build and acquire new sites, and as they further consolidate med-surg spend with Medline. In addition, we intend to further extend our leading position by adding new Prime Vendor relationships, increasing the number of non-Prime Vendor customers that choose Medline Brand, continuing our channel expansion, developing new products, executing on selective M&A opportunities, and scaling our international footprint. For the nine months ended September 27, 2025, we generated net sales of $20.6 billion, net income of $1.0 billion, and Adjusted EBITDA of $2.7 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 12.9%. During that period, 48.4% of total net sales and 81.2% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 51.6% of total net sales and 18.8% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. For the year ended December 31, 2024, we generated net sales of $25.5 billion, net income of $1.2 billion, and Adjusted EBITDA of $3.4 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 13.2%. During that period, 49.1% of total net sales and 83.5% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 50.9% of total net sales and 16.5% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. Our principal executive offices are located in Northfield, Illinois.

Market Capitalization
$45.62 billion
P/E Ratio
43.92
Consensus Rating
Moderate Buy
Consensus Price Target
$46.88 (+35.1% Upside)
Volume
7.78 million shares
Average Volume
7.92 million shares
Today's Range
$34.47
▼
$35.29
50-Day Range
$31.64
▼
$42.04
52-Week Range
$31.49
▼
$50.88
Dividend Yield
N/A
Veeva Systems stock logo

41. Veeva Systems NYSE:VEEV

$280.95 +6.11 (+2.22%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$281.12 +0.17 (+0.06%)
As of 09/25/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • Veeva Systems Inc. recently launched the Veeva Study Builder Agent, an AI solution that configures clinical trial systems directly from a study protocol, which streamlines trial setup and positions the company as a leader in AI-driven life sciences software.
  • The company secured a new top 20 biopharma commitment for its Vault CRM platform, adding to recent selections by major players like Amgen, Biogen, Eli Lilly, and Regeneron, which demonstrates strong market leadership and continued enterprise adoption.
  • Veeva Systems Inc. reported strong financial performance in its most recent quarter with revenue of $927.96 million, exceeding analyst estimates of $905.38 million, and earnings per share of $2.35, which beat the consensus estimate of $2.23.

Cons of Veeva Systems

  • Insiders have been selling shares recently, with Thomas D. Schwenger selling 10,000 shares on August 27, 2026, and Priscilla Hung selling 750 shares on September 9, 2026, which may signal a lack of confidence from company leadership.
  • The stock has a high price-to-earnings ratio of 42.15, which is significantly above the market average, indicating that the stock may be overvalued relative to its current earnings.
  • Short interest has increased slightly, with 4,964,067 shares shorted as of September 15, 2026, representing 3.43% of the float, which suggests some investors are betting against the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.44 billion
P/E Ratio
46.21
Consensus Rating
Moderate Buy
Consensus Price Target
$284.88 (+1.4% Upside)
Volume
1.74 million shares
Average Volume
1.55 million shares
Today's Range
$275.91
▼
$282.81
50-Day Range
$179.36
▼
$285.56
52-Week Range
$148.05
▼
$310.50
Dividend Yield
N/A
IQVIA stock logo

42. IQVIA NYSE:IQV

$270.12 -4.90 (-1.78%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$270.50 +0.38 (+0.14%)
As of 09/25/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • IQVIA Holdings Inc. recently reported strong second-quarter results, beating analyst expectations with earnings per share of $3.15 compared to a consensus estimate of $3.03, while revenue of $4.37 billion also exceeded the projected $4.30 billion, demonstrating the company's ability to outperform market forecasts and drive shareholder value through operational efficiency.
  • The stock is currently trading at $275.38, which is near its 52-week high of $277.40, reflecting a significant upward momentum and strong investor confidence in the company's trajectory, as the share price has risen substantially from its 52-week low of $154.50 over the past year.
  • Analysts have recently raised their price targets and ratings, with TD Cowen lifting its target to $288.00 and JPMorgan Chase raising its target to $285.00, both assigning buy or overweight ratings, which suggests that financial experts believe the current valuation does not fully capture the company's future growth potential in the life sciences sector.

Cons of IQVIA

  • The company has a debt-to-equity ratio of 2.18, which indicates a high level of leverage relative to its equity, potentially increasing financial risk and interest expenses that could pressure future earnings if interest rates remain elevated or if revenue growth slows down.
  • Corporate insiders have been selling shares recently, with James G. Berkshire selling 2,668 shares and Bhavik Patel selling 1,855 shares in recent months, which may signal that company executives are taking advantage of the current high stock price to reduce their personal exposure to the company's stock.
  • The current price-to-earnings ratio of 23.78 is relatively high compared to some peers, suggesting that the stock may be overvalued if the company's earnings growth does not continue to accelerate, which could lead to a correction in the stock price if market sentiment shifts or if economic conditions deteriorate.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.50 billion
P/E Ratio
33.51
Consensus Rating
Moderate Buy
Consensus Price Target
$248.00 (-8.2% Downside)
Volume
1.10 million shares
Average Volume
1.54 million shares
Today's Range
$269.43
▼
$274.90
50-Day Range
$198.96
▼
$275.38
52-Week Range
$154.50
▼
$277.40
Dividend Yield
N/A
Revolution Medicines stock logo

43. Revolution Medicines NASDAQ:RVMD

$204.97 +5.11 (+2.56%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$205.48 +0.50 (+0.25%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$43.93 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$230.15 (+12.3% Upside)
Volume
2.52 million shares
Average Volume
1.95 million shares
Today's Range
$197.97
▼
$211.51
50-Day Range
$180.39
▼
$221.15
52-Week Range
$42.78
▼
$224.31
Dividend Yield
N/A
Waters stock logo

44. Waters NYSE:WAT

$433.97 +3.67 (+0.85%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$433.64 -0.33 (-0.08%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$42.59 billion
P/E Ratio
108.22
Consensus Rating
Moderate Buy
Consensus Price Target
$434.60 (+0.1% Upside)
Volume
662,530 shares
Average Volume
635,039 shares
Today's Range
$425.67
▼
$435.93
50-Day Range
$357.29
▼
$433.97
52-Week Range
$282.77
▼
$436.34
Dividend Yield
N/A
IDEXX Laboratories stock logo

45. IDEXX Laboratories NASDAQ:IDXX

$519.26 +5.87 (+1.14%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$518.34 -0.91 (-0.18%)
As of 09/25/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The company recently acquired CoVetAI, a veterinary AI software firm, which expands its AI-native software capabilities to improve veterinary workflows, diagnostics, and practice performance, signaling a strategic move to enhance its digital ecosystem and recurring revenue streams.
  • IDEXX Laboratories, Inc. reported strong second-quarter results with earnings per share of $4.27, beating the consensus estimate of $3.94, and revenue of $1.22 billion, which exceeded expectations and demonstrated double-digit growth in reference laboratory and VetLab recurring revenue.
  • Executives reaffirmed the company's long-term growth framework at the Morgan Stanley Global Healthcare Conference, targeting more than 10% organic revenue growth and more than 15% earnings-per-share growth, supported by a $45 billion global diagnostics total addressable market and continued innovation in point-of-care diagnostics.

Cons of IDEXX Laboratories

  • The company expects a decline in clinical veterinary visits, with CFO Andrew Emerson stating an anticipated 1.5% decline in visits during the second half of the year, which could pressure revenue growth despite a larger pet population and more medicalized pets.
  • Several analysts have recently downgraded or lowered their price targets, including Weiss Ratings downgrading from "hold (c+)" to "hold (c)" and Barclays cutting its price target from $800.00 to $710.00, reflecting concerns about the current valuation and market conditions.
  • Insider selling has been notable, with CEO Jay Mazelsky selling 23,326 shares in February 2026 and Director Lawrence D. Kingsley selling 2,203 shares in September 2026, which may signal a lack of confidence from company leadership at current price levels.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.91 billion
P/E Ratio
36.52
Consensus Rating
Moderate Buy
Consensus Price Target
$747.00 (+43.9% Upside)
Volume
331,112 shares
Average Volume
491,787 shares
Today's Range
$507.01
▼
$520.16
50-Day Range
$504.70
▼
$595.76
52-Week Range
$500.61
▼
$769.98
Dividend Yield
N/A
Illumina stock logo

46. Illumina NASDAQ:ILMN

$270.00 -3.90 (-1.42%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$268.99 -1.01 (-0.37%)
As of 09/25/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. More about Illumina

Pros of Illumina

  • Illumina, Inc. recently reported strong financial performance for the quarter ended July 30, 2026, with earnings per share of $1.31, which beat the consensus estimate of $1.23, and revenue of $1.16 billion, exceeding the expected $1.13 billion, demonstrating the company's ability to outperform market expectations and drive shareholder value through robust operational execution.
  • The stock has experienced significant momentum, reaching a 52-week high of $277.95 and trading at a current price of $270.00 as of September 25, 2026, reflecting a year-to-date return of over 100% and indicating strong investor confidence in the company's growth trajectory and market position in the life sciences sector.
  • Illumina, Inc. has raised its full-year 2026 earnings per share guidance to a range of $5.30 to $5.40, signaling management's confidence in continued revenue growth and profitability, which supports the narrative of sustainable expansion in genomic analysis technologies and clinical adoption of its sequencing platforms.

Cons of Illumina

  • The stock trades at a price-to-earnings ratio of 53.18, which is significantly higher than the consensus price target of $199.12, suggesting that the current valuation may be stretched relative to analyst expectations and could be vulnerable to correction if growth does not continue to accelerate at the pace implied by the market price.
  • Insider selling has been substantial, with Director Keith Meister selling over 3 million shares in the past six months for an estimated $591 million, and other executives also reducing their positions, which may signal a lack of confidence from those with the most intimate knowledge of the company's internal operations and future prospects.
  • Short interest in Illumina, Inc. has increased to 10.58 million shares as of September 15, 2026, representing 7.22% of the float, indicating that a significant portion of the market is betting against the stock's future performance, which could lead to volatility and downward pressure if the bearish sentiment gains further traction.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.77 billion
P/E Ratio
50.37
Consensus Rating
Hold
Consensus Price Target
$199.13 (-26.3% Downside)
Volume
5.03 million shares
Average Volume
3.87 million shares
Today's Range
$267.66
▼
$276.97
50-Day Range
$184.68
▼
$273.90
52-Week Range
$88.00
▼
$277.95
Dividend Yield
N/A
BeOne Medicines stock logo

47. BeOne Medicines NASDAQ:ONC

$360.85 +0.88 (+0.24%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$356.94 -3.91 (-1.08%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$39.62 billion
P/E Ratio
63.53
Consensus Rating
Buy
Consensus Price Target
$402.71 (+11.6% Upside)
Volume
375,853 shares
Average Volume
376,161 shares
Today's Range
$358.51
▼
$365.00
50-Day Range
$310.58
▼
$376.86
52-Week Range
$253.95
▼
$385.22
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

48. Alnylam Pharmaceuticals NASDAQ:ALNY

$255.96 +6.37 (+2.55%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$257.74 +1.79 (+0.70%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Alnylam Pharmaceuticals, Inc. recently reported strong financial performance, with quarterly revenue of $1.29 billion, representing a 66.9% year-over-year increase, and earnings per share of $1.84, which exceeded analyst consensus estimates of $1.63, demonstrating robust commercial execution and profitability.
  • The company maintains a favorable balance sheet with a quick ratio of 2.99 and a current ratio of 3.05, indicating strong liquidity and the ability to meet short-term obligations, while a debt-to-equity ratio of 0.75 suggests a manageable level of leverage for a biopharmaceutical firm.
  • Analyst sentiment remains positive with a consensus rating of "Moderate Buy" from 23 research firms, and a recent price target of $455.00 from HC Wainwright implies significant upside potential from the current stock price of $255.96, reflecting confidence in the company's long-term growth trajectory.

Cons of Alnylam Pharmaceuticals

  • The current stock price of $255.96 is significantly below the 52-week high of $495.55, indicating a substantial decline in valuation over the past year, which may reflect ongoing market concerns about the company's growth prospects or competitive positioning.
  • Short interest has increased recently, with 7,194,097 shares shorted as of September 15, 2026, representing a 13.47% month-over-month increase, suggesting that a significant portion of the market is betting against the stock's future performance.
  • Several major financial institutions have recently lowered their price targets, including Morgan Stanley reducing its target from $400.00 to $300.00 and Citigroup lowering its target from $380.00 to $340.00, indicating a more cautious outlook on the company's near-term earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.25 billion
P/E Ratio
47.58
Consensus Rating
Moderate Buy
Consensus Price Target
$367.20 (+43.5% Upside)
Volume
1.08 million shares
Average Volume
1.49 million shares
Today's Range
$247.51
▼
$256.66
50-Day Range
$205.48
▼
$288.41
52-Week Range
$197.81
▼
$495.55
Dividend Yield
N/A
Biogen stock logo

49. Biogen NASDAQ:BIIB

$227.60 +1.24 (+0.55%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$226.84 -0.76 (-0.33%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

  • Biogen Inc. recently achieved a new 52-week high, with the stock trading at $226.36 as of September 24, 2026, reflecting strong market confidence and a significant upward trend from its 52-week low of $135.39.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $3.60, which significantly exceeded the analyst consensus estimate of $2.94, while also generating revenue of $2.74 billion, surpassing expectations of $2.46 billion.
  • Biogen Inc. has secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer’s disease, a development that enhances patient accessibility and potentially broadens the treatment reach for this critical neurological condition.

Cons of Biogen

  • Biogen Inc. carries a high price-to-earnings ratio of 40.06, which suggests the stock is priced at a significant premium relative to its current earnings, potentially leaving little room for error if future growth does not meet elevated expectations.
  • The company does not currently pay a dividend, as indicated by a dividend yield of 0.00%, which may be a drawback for income-focused investors seeking regular cash flow from their biotechnology holdings.
  • Short interest in the stock has been increasing, with the number of shares shorted rising to 5,817,797 as of the September 15, 2026 record date, representing a month-to-month increase of 1.59% and suggesting that some market participants are betting against the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.63 billion
P/E Ratio
40.28
Consensus Rating
Moderate Buy
Consensus Price Target
$230.14 (+1.1% Upside)
Volume
957,967 shares
Average Volume
910,938 shares
Today's Range
$223.76
▼
$228.92
50-Day Range
$197.74
▼
$227.60
52-Week Range
$135.39
▼
$229.19
Dividend Yield
N/A
Royalty Pharma stock logo

50. Royalty Pharma NASDAQ:RPRX

$58.21 -0.08 (-0.14%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$58.75 +0.54 (+0.93%)
As of 09/25/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The stock is currently trading at $57.65, which is below the consensus price target of $61.29 set by eight analysts who have all issued a Buy rating, suggesting potential for further upside as the company continues to beat earnings estimates.
  • Royalty Pharma plc recently reported earnings per share of $1.32 for the quarter, exceeding the consensus estimate of $1.27, demonstrating strong profitability with a net margin of 32.14% and a return on equity of 30.01%.
  • The company offers a dividend yield of 1.61% with a recent quarterly payment of $0.235 per share, providing a steady income stream for investors while maintaining a payout ratio of 64.83% that leaves room for future growth.

Cons of Royalty Pharma

  • The stock has experienced a significant run-up of 136%, leading some analysts to view it as richly priced despite the recent earnings beat, which may limit near-term growth potential.
  • Recent insider activity shows a trend of selling, with executives like Christopher Hite and Marshall Urist selling significant portions of their holdings under Rule 10b5-1 plans, which can signal a lack of confidence in the current valuation.
  • The company faces risks from clinical trial failures, such as the Phase 3 failure of pelacarsen in the Lp(a)HORIZON trial, which could impact the value of its royalty portfolio if other development-stage candidates fail to meet endpoints.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.47 billion
P/E Ratio
40.15
Consensus Rating
Buy
Consensus Price Target
$61.29 (+5.3% Upside)
Volume
1.87 million shares
Average Volume
3.22 million shares
Today's Range
$57.68
▼
$58.50
50-Day Range
$56.77
▼
$63.96
52-Week Range
$34.63
▼
$64.38
Dividend Yield
1.61%